好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A systematic review of behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate in real-world studies
General Neurology
General Neurology Posters (7:00 AM-5:00 PM)
080
Understand the real-world incidences of and discontinuations due to the behavioral adverse events (BAEs) of irritability, anger, and aggression in patients with epilepsy treated with brivaracetam (BRV), levetiracetam (LEV), perampanel (PER), and topiramate (TPM), and BAEs in patients switching from LEV to BRV. 
Tolerability data from randomized, controlled trials provide only a glimpse into the incidence of BAEs in the real world as patients with comorbidities or other risk factors for these events are often excluded. Observational postmarketing studies may fill this gap, but have not been summarized. 

A systematic review of published literature using the Cochrane Library, PubMed/MEDLINE, and Embase was performed to identify real-world studies reporting incidences of irritability, anger, or aggression with BRV, LEV, PER, or TPM in adults with epilepsy either as discrete outcomes or adverse events. The incidences and discontinuation due to each, as well as BAEs in patients switching from LEV to BRV, were summarized. Where possible, weighted means were calculated, but not statistically compared.
A total of 1500 records were identified, and 44 published articles (42 studies) met the inclusion criteria. While a wide range of results was reported across studies, weighted mean incidences were: 5.6%, 9.9%, 12.3%, and 3.1% for BRV, LEV, PER, and TPM, respectively, for irritability; 3.3%*, 2.5%, 2.0%, and 0.2%* for anger; and 2.5%, 2.6%, 4.4%, and 0.5%* for aggression. Weighted mean discontinuation rates were: 0.8%*, 3.4%, 3.0%, and 2.2% for irritability and 0.8%*, 2.4%, 9.2%, and 1.2%* for aggression. There were no discontinuations for anger. Switching from LEV to BRV led to improvement of BAEs in 33.3% to 83.0% of patients. *denotes only 1 study. 

Differences in methods, BAE definitions, and populations across studies make a conclusion difficult. However, switching from LEV to BRV appears to result in improvement of BAEs.
Authors/Disclosures
Bernhard Steinhoff
PRESENTER 		Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Bernhard Steinhoff has received personal compensation in the range of $0-$499 for serving as a Consultant for B.Braun Melsungen. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuraxpharm. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Precisis. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Bernhard Steinhoff has received research support from UCB. The institution of Bernhard Steinhoff has received research support from Eisai. The institution of Bernhard Steinhoff has received research support from SK LIfe Science.
Pavel Klein, MD, FAAN (Mid-atlantic Epilepsy and Sleep Center) The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aquestive. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Sience. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alliance. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle Therapeutics. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Aquestive. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for SK Life Sciences. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion. Dr. Klein has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for PrevEp. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Fenwick . Dr. Klein has received research support from DOD/CURE.
Henrik Klitgaard (UCB) Mr. Klitgaard has received personal compensation for serving as an employee of UCB Inc. Mr. Klitgaard has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for UCB Inc.
Cedric Laloyaux, PhD (UCBMedical Affairs Center of Expertise) Dr. Laloyaux has received personal compensation for serving as an employee of UCB.
Brian D. Moseley, MD Dr. Moseley has received personal compensation for serving as an employee of UCB. Dr. Moseley has received personal compensation for serving as an employee of Neurocrine Biosciences Inc. Dr. Moseley has or had stock in UCB.
No disclosure on file
Felix Rosenow No disclosure on file
Joseph I. Sirven, MD, FAAN (Mayo Clinic) Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona. Dr. Sirven has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Sirven has received publishing royalties from a publication relating to health care. Dr. Sirven has received personal compensation in the range of $10,000-$49,999 for serving as a Host/ Co producer with WJCT Public Media. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Federal Aviation Administration .
Brien J. Smith, MD, FAAN (Henry Ford Health) Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma.
John M. Stern, MD, FAAN Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Science. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharma. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for LivaNova. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for LivaNova. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life Sciences. Dr. Stern has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Stern has stock in DEARhealth. Dr. Stern has stock in Ceribell. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care.
Manuel Toledo Manuel Toledo has nothing to disclose.
No disclosure on file
Vicente Villanueva Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rapport. Vicente Villanueva has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Vicente Villanueva has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Angelini. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI. Vicente Villanueva has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Paladin. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz pharmaceutical.